Emerging biomarkers in head and neck cancer in the era of genomics
Head and neck cancer (HNC) broadly includes carcinomas arising from the mucosal
epithelia of the head and neck region as well as various cell types of salivary glands and the …
epithelia of the head and neck region as well as various cell types of salivary glands and the …
miR-212/132 expression and functions: within and beyond the neuronal compartment
A Wanet, A Tacheny, T Arnould… - Nucleic acids …, 2012 - academic.oup.com
During the last two decades, microRNAs (miRNAs) emerged as critical regulators of gene
expression. By modulating the expression of numerous target mRNAs mainly at the post …
expression. By modulating the expression of numerous target mRNAs mainly at the post …
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
A main limitation of therapies that selectively target kinase signalling pathways is the
emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the …
emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the …
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Several discoveries have paved the way to personalise cancer medicine and a tremendous
gain of knowledge in genomics and molecular mechanisms of cancer progression …
gain of knowledge in genomics and molecular mechanisms of cancer progression …
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
TM Brand, M Iida, DL Wheeler - Cancer biology & therapy, 2011 - Taylor & Francis
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase belonging to the
HER family of receptor tyrosine kinases. Receptor activation upon ligand binding leads to …
HER family of receptor tyrosine kinases. Receptor activation upon ligand binding leads to …
AXL mediates resistance to cetuximab therapy
TM Brand, M Iida, AP Stein, KL Corrigan… - Cancer research, 2014 - AACR
The EGFR antibody cetuximab is used to treat numerous cancers, but intrinsic and acquired
resistance to this agent is a common clinical outcome. In this study, we show that …
resistance to this agent is a common clinical outcome. In this study, we show that …
miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor
Numerous microRNAs (miRNAs) are reported as differentially expressed in cancer, however
the consequence of miRNA deregulation in cancer is unknown for many miRNAs. We report …
the consequence of miRNA deregulation in cancer is unknown for many miRNAs. We report …
Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer
CJ Chang, CC Hsu, CH Chang, LL Tsai… - Oncology …, 2011 - spandidos-publications.com
Oral squamous cell carcinoma (OSCC) is a prevalent cancer worldwide. Let-7 family has
been shown to function as a tumor suppressor through regulating multiple oncogenic …
been shown to function as a tumor suppressor through regulating multiple oncogenic …
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR–MET interaction and activation of MET signaling in colon …
T Troiani, E Martinelli, S Napolitano, D Vitagliano… - Clinical cancer …, 2013 - AACR
Purpose: Although cetuximab, an anti-EGF receptor (EGFR) monoclonal antibody, is an
effective treatment for patients with KRAS wild-type metastatic colorectal cancer (mCRC), its …
effective treatment for patients with KRAS wild-type metastatic colorectal cancer (mCRC), its …
Precision medicine approaches to overcome resistance to therapy in head and neck cancers
S Ortiz-Cuaran, J Bouaoud, A Karabajakian… - Frontiers in …, 2021 - frontiersin.org
Head and neck squamous cell carcinoma (HNSCC) is the sixth most incident cancer
worldwide. More than half of HNSCC patients experience locoregional or distant relapse to …
worldwide. More than half of HNSCC patients experience locoregional or distant relapse to …